

# **SUVEN Life Sciences**

#### Communication to investors Dec 2014

10-Feb-15

#### Risk statement



Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



#### FINANCIAL QUICK VIEW


	Q3 Dec 14	PE Dec 14
Growth in revenue	9%	8.17%
Growth in PAT	-11.55%	-17.85%
Growth in EBIDTA	-9.22%	-13.88%
Growth in Pre-R&D EBIDTA	-3.17%	-12.88%
Increase in R&D Costs	31.49%	-7.98%
R&D to sales	9.76%	7.89%

# MAJOR PROFITABILITY RATIOS

	Q3 Dec 14	PE Dec 14
PAT to Income	25%	22%
EBIDTA to Income	39%	36%
Cash Flow to Income	28%	26%
Pre-R&D EBITDA to Income	48%	44%




#### **INCOME COMPARISON**






# **PROFIT COMPARISON**



2014-15 Q3 results




# EBIDTA COMPARISON






# R & D – EXPENDITURE






#### **PRE-R&D EBIDTA**



10-Feb-15



#### PRE-R&D CASHFLOW



#### Status for the period ended Dec 2014

- Suven has 725 product patents for 26 inventions and 37 process patents for 7 inventions
- Number of active CRAMS projects 108
- SUVN 502 completed Phase 1b clinical trial in USA and is in preparation for entering into Phase 2a clinical trial.
- SUVN-G3031 for Cognition in Alzheimer's Disease commenced
  Phase 1 Clinical Trial in USA under US-IND 123179